Apoptosis and fas system are significantly involved in the process of liver cirrhosis converting into hepatocellular carcinoma

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 21, Issue 2, 2001, Pages 126-129

  Peng, Zhihai ^a   Tang, Huamei ^a   Ling, Yun ^a   Han, Guoxin ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

Apoptosis; Fas ligand; Fast; Hepatocellular carcinoma; Liver cirrhosis; Soluble Fas

Indexed keywords

BIOASSAY; BIOCHEMISTRY; CARCINOGENS; ENZYMES; HISTOLOGY; IMMUNOLOGY; PATIENT MONITORING;

APOPTOSIS; FAS LIGAND; FAST; HEPATOCELLULAR CARCINOMA (HCC); LIVER CIRRHOSIS; SOLUBLE FAS;

BIOMEDICAL ENGINEERING;

FAS ANTIGEN; FASL PROTEIN; MEMBRANE PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; BIOSYNTHESIS; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; MALE; METABOLISM; PATHOLOGY;

ADULT; AGED; ANTIGENS, CD95; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMAN; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T;

EID: 24744434733     PISSN: 0257716X     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02888075     Document Type: Article

References (15)

1. Yu, Z Y, Tang Z Y, Yang B H et al. Viral hepatitis (HBV and HCV) background in Chinese patients with hepatocellular carcinoma. Clin J Cancer Res, 1994, 6: 79
2. Williams G T. Programmed cell death: apoptosis and oncogenesis. Cell, 1991, 65: 1097
3. Nagata S, Golstein P. The Fas death factor. Science, 1995, 267: 1449
4. Hayashi N, Mita E. Fas system and apoptosis in viral hepatitis. J Gastroenterol Hepatol, 1997, 12: S223
5. Schulte-hermann R, Brusch W, Grasl-kraupp B et al. Active cell death (apoptosis) in liver biology and disease. Progress in liver disease, 1995, 13: 1
6. Benedetti A, Jezequel A M, Orlandi F. A quantitative evaluation of apoptotic bodies in rat liver. Liver, 1988, 8: 172
7. Grasl-Kraupp B, Bursch W, Ruttkay-Nedecky B et al. Food restriction eliminates preneoplastic cells through apoptosis and antagonizes carcinogenesis in rat liver. Proc Natl Acad Sci USA, 1994, 91: 9995
8. Ogasawara J, Watanabe-Fukunaga R, Adachi M et al. Lethal effect of the anti-Fas antibody in mice. Nature, 1993, 364: 806
9. Galle P R, Hofmann W J, Walczak H et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med, 1995, 182: 1223
10. Ito Y, Takeda T, Umeshita K et al. Fas antigen expression in hepatocellular carcinoma tissues. Oncol Reports, 1998, 5: 41
11. Yano H, Fukuda K, Haramaki M et al. Expression of Fas and anti-Fas-mediated apoptosis in human hepatocellular carcinoma cell lines. J Hepatol, 1996, 25: 454
12. Papoff G, Cascino T, Eramo A et al. An N-terminal domain shared by Fas/APO-1 (CD95) soluble variants prevents cell death in vitro. J Immunol, 1996, 156: 4622
13. Hanabuchi S, Koyanagi M, Kawasaki A et al. Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc Natl Acad SciUSA, 1994, 91: 4930
14. Gregory P, Midis, Yu S et al. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Research, 1996, 56: 3870
15. Jodo S, Kobayashi S, Nakajima Y et al. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin Exp Immunol, 1998, 112: 166